SEC Company Response from Antiaging Quantum Living Inc. (AAQL) (CIK 0001672571) (AAQL) — Apr 21, 2017
Antiaging Quantum Living Inc. (AAQL) (CIK 0001672571)
Date: April 21, 2017 · CIK: 0001672571 · Accession: 0001672571-17-000007
AI Filing Summary & Sentiment
File numbers found in text: 333-211051
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
CORRESP for the SEC letter of the Registration Satement on Form S-1
Achison INC
CIK: 0001672571
3906 Main Street, 207
Flushing, NY11354
April 21, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Real Estate and Commodities
100 F Street, N.E.
Washington, DC 20549
Attention:
Folake Ayoola
Stacie Gorman
Paul Cline
Wilson Lee
Re: Achison Inc
Amendment No. 7 to Registration Satement on Form S-1
Filed March 24, 2017
File No. 333-211051
General
1. We note your response to our prior comment 1 and your revised disclosure that "Lansdale
Inc will intend to hold sufficient shares to become the parent of the Corporation." We
further note your disclosure on page 6 that "Lansdale Inc is a holding company..." and
"After two yeay... Lansdale Inc will resale (sic) some shares of the Corporation...which
Lansdale Inc will be holding." It appears that an investment decision has been made that
Lansdale will purchase shares from you. Please tell us how this complies with Section 5
of the Securities Act.
We removed: "Lansdale Inc is a holding company..." and "After two years... Lansdale Inc will resale (sic) some shares of the Corporation...which
Lansdale Inc will be holding."
Please see the amended contents of Risk Factors 2 (5) on page 6 of the Form S-1/A on April 21, 2017.
2. We note your disclosure throughout the prospectus that Lansdale is a holding company.
We further note your disclosure on page 6 where you indicate that you are setting up
several companies in the same industry, namely Landbay, Lemont, Linton and Dewriver.
Please revise your disclosure to clarify whether you or Lansdale is the holding company
for these entities.
Please see the amended contents of Risk Factors 2 (10) on page 7 of the Form S-1/A on April 21, 2017.
Prospectus Summary, page 6
3. We note your response to our prior comment 3 and your revised disclosure in paragraph 3
that you will not reimburse Blueville for expenses paid to date. Please reconcile this
disclosure with your disclosure on page 10 where you indicate that you will reimburse
Blueville for auditing and legal fees.
Please see the amended contents of Interests of Named Experts and Counsel 1 and 2 on page 10 of the Form S-1/A on April 21, 2017.
Exhibit 5. Legal Opinion
4. We note your response to our prior comment 4. The introductory language of paragraph 6
of the legal opinion continues to serve as an unacceptable qualification of the opinion in
paragraph 9, especially as it relates to parts (ii), (iii), and (iv) of paragraph 6. Please ask
counsel to revise the introductory language or to delete parts (ii), (iii), and (iv) of
paragraph 6. Refer to the Division of Corporation Finance's Staff Legal Bulletin No. 19
for guidance.
Please see the amended contents of Exhibits 5 of the Form S-1/A on April 21, 2017.
Exhibit 23
5. Please include an updated consent from your independent accountant in the pre-effective
amendment.
Please see the amended contents of Exhibits 23.3 of the Form S-1/A on April 21, 2017.
Wanjun Xie
Wanjun Xie
President
Achison Inc
Date: April 21, 2017